TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05604131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferiprone Tablets
Description: Deferiprone tablets are the active medication for the active arm of the study groups. Randomization will be done by investigational drug services pharmacist and intervention will be double-blinded to investigators and patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferiprone Tablets
Description: Deferiprone tablets are the active medication for the active arm of the study groups. Randomization will be done by investigational drug services pharmacist and intervention will be double-blinded to investigators and patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Deferiprone placebo is the non-medicated formulation for a control arm of the study groups.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Deferiprone placebo is the non-medicated formulation for a control arm of the study groups.
Study: NCT06147076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support Network Counseling Intervention
Description: Social support counseling intervention for kidney transplant candidates along with their social support networks.
Study: NCT04942028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure
Description: Systematic confrontation with stimuli associated with symptom-related distress, to achieve therapeutic changes in cognitions or behavior

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized education
Description: Standardized routine care education for individuals suffering from distress related to somatic symptoms, primarily focusing on healthy lifestyle behaviors such as sleep, diet, and exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged assessment
Description: Patients are encouraged to keep a rudimentary symptom diary to track if and how their symptoms interact with mood and lifestyle behaviors
Study: NCT05638087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone Oral Suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Placebo Oral Mix
Study: NCT05937347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU + UP4H
Description: Group treatment protocol of 8 weeks (approximately 105 minutes per week, 75 of face-to-face and 30 of virtual intervention).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU + M4H
Description: Group treatment protocol of 8 weekly 75 minute sessions (face-to-face intervention).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU + CT
Description: Group treatment protocol of 8 weekly 60 minutes sessions (virtual intervention).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Standard pharmacological treatment usually provided to children with ADHD.
Study: NCT05775562

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pre and post dive examinations
Description: Performing pre-dive examinations:~- EFR by plethysmography cabin~Realization of the examinations the day of the dive:~* Portable Spirometry~* Pulmonary ultrasound~* Cardiac ultrasound~* Measurement of circulating bubbles~* ECG~* Venous blood sampling (biological collection)~* Water balance (Δweight/water intake)~* EFR by plethysmography cabin~* Weight measurement~Realization of the examinations the day after the dive:~* Venous blood sample (biological collection)~* Portable Spirometry~* Pulmonary ultrasound~* Cardiac ultrasound~* Weight measurement
Study: NCT05928286

Intervention type: DRUG
Intervention: Remaxol
Description: The perioperative infusion of Remaxol® (Inosine + Meglumine + Methionine + Nicotinamide + Succinic acid)
Study: NCT05838196

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound
Description: Point-of-care ultrasound performed during clinic appointment
Study: NCT05898464

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant zoster vaccination
Description: Two doses of recombinant zoster vaccine(Shingrix®), 2 months apart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant zoster vaccination
Description: Two doses of recombinant zoster vaccine(Shingrix®), 2 months apart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant zoster vaccination
Description: Two doses of recombinant zoster vaccine(Shingrix®), 2 months apart
Study: NCT04723147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa Levodopa
Description: Patients will receive L-DOPA at doses ranging from 150 to 450 mg administered at a ratio of 1 mg carbidopa for every 4 mg L-DOPA. Starting dose is 150 mg/day with dose escalation 150 mg/day per week to a final dose of 450 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa Levodopa
Description: Patients will receive L-DOPA at doses ranging from 150 to 450 mg administered at a ratio of 1 mg carbidopa for every 4 mg L-DOPA. Starting dose is 150 mg/day with dose escalation 150 mg/day per week to a final dose of 450 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 1 placebo tablet matching the Carbidopa Levodopa tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 1 placebo tablet matching the Carbidopa Levodopa tablet.
Study: NCT05608902

Intervention type: OTHER
Intervention: Dynamic full-field optical coherence tomography analysis of skin biopsy or resection
Description: Dynamic full-field optical coherence tomography analysis of skin biopsy or resection in the dermatology department before conventional histopathological analysis
Study: NCT05503563

Intervention type: PROCEDURE
Intervention: terta modal bladder preservation
Description: neoadjuvant chemotherapy, partial cystectomy, radiotherapy
Study: NCT05908825

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo serum
Description: Placebo serum will be randomly assigned as Product A or Product B to be applied to one side of the face.
Study: NCT06279871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-2303
Description: Self-Amplifying RNA COVID-19 vaccine (Omicron XBB.1.5)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-2303
Description: Self-Amplifying RNA COVID-19 vaccine (Omicron XBB.1.5)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-2303
Description: Self-Amplifying RNA COVID-19 vaccine (Omicron XBB.1.5)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-2303
Description: Self-Amplifying RNA COVID-19 vaccine (Omicron XBB.1.5)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ARCT-2303
Description: Self-Amplifying RNA COVID-19 vaccine (Omicron XBB.1.5)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ARCT-2303
Description: Self-Amplifying RNA COVID-19 vaccine (Omicron XBB.1.5)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Licensed cell-based influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Licensed cell-based influenza vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Licensed cell-based influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine, adjuvanted
Description: Licensed influenza vaccine, adjuvanted

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine, adjuvanted
Description: Licensed influenza vaccine, adjuvanted

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine, adjuvanted
Description: Licensed influenza vaccine, adjuvanted

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% saline

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.9% saline

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.9% saline
Study: NCT06655610

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Trigeminal Nerve Stimulation
Description: Active eTNS will be provided by applying single, bipolar pulses of 0.5 milliseconds duration at a frequency of 125 hertz, with an active period of 30 seconds on/off. Stimulation current will range from 0.2 mili ampere (mA) to 10 mA. The level of current, which is noticeable, yet within the level of comfort, will be identified for each patient by titration at baseline. Depending on the perception of stimulation, the level of current may be altered during the four weeks of treatment, by either the guardian or adolescent in control of the settings.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: The stimulator and patches will be identical in appearance to the active treatment. The guardian/the adolescent will be informed to administer the device in the same fashion as with active treatment. The sham device will however be programmed to only apply stimulation for 30 seconds every hour during sleep, optimally at a frequency of maximum 2 Hz. As with the active eTNS, the sham stimulation current will range from 0.2 to 10 mA. Such settings have previously been considered to induce the sensation of a current applied to the forehead as seen with active treatment, yet without it being therapeutically effective. Stimulation will be directed through an internal resister, which ensures draining of batteries and need for recharging after each session. The manufacture of the eTNS device (Neurosigma) will oversee the programming the sham device.
Study: NCT06588504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: Participants will receive s.c. injection of dasiglucagon.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: Participants will receive s.c. injection of dasiglucagon.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: Participants will receive s.c. injection of dasiglucagon.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Participants will receive i.m. injection of glucagon.
Study: NCT06607263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mouthwash CPC+Zn+F
Description: A mouthwash containing CPC + Zn and fluoride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Essential oils mouthrinse
Description: Essential oils mouthrinse

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental floss
Description: Dental floss

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toothpaste
Description: A commercially available fluoride toothpaste

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste
Description: A commercially available fluoride toothpaste

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste
Description: A commercially available fluoride toothpaste

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toothbrush
Description: A commercially available adult toothbrush

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrush
Description: A commercially available adult toothbrush

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrush
Description: A commercially available adult toothbrush
Study: NCT05319028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mivavotinib
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mivavotinib
Description: oral tablet
Study: NCT06726928

Intervention type: DEVICE
Group type: OTHER
Intervention: Sinus Stenting
Description: Stenting of symptomatic sinus stenosis
Study: NCT06735001

Intervention type: PROCEDURE
Group type: OTHER
Intervention: FA ablation
Description: Ablation of the FA

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Lab test
Description: Blood collection

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Lab test
Description: Blood collection
Study: NCT06734559

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Patients who have not antibiotic treatment for acute apical periodontitis in the last month and have not taken any anti-inflammatory medication in the past 24 hours.
Description: Patients with acute apical periodontitis will first have masseter muscle measurements in the relevant area and then the decayed tooth will be treated with calcium hydroxide for 14 days. Then the dressing will be applied with calcium hydroxide again. At the end of 28 days, the patient will be measured again by ultrasonography and the initial and final data will be compared.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: patients who have not acute apical periodontitis
Description: Masseter measurements will be made from day 1 to day 28 in healthy subjects without acute apical periodontitis.
Study: NCT06734910

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HealthyPregnancy
Description: A digital care guide comprising of:~1. Information about diet, exercise and mental wellbeing in pregnancy. Presented in text, video and audio material featuring various healthcare professionals.~2. Online exercise. Access to live online structured physical exercise twice a week and to an off line library of exercise videos.~3. Chat function with possibility to chat safely with healthcare professionals.~4. Push-notifications reminding the participants of upcoming antenatal appointments.~In addition an invitation to monthly café sessions focusing on e.g., mental health, parenting skills, breastfeeding and healthy lifestyle.
Study: NCT06736418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225Ac-ABD147
Description: A delta-like ligand 3 (DLL3)-targeting antibody fragment conjugated with a linker-chelator that effectively coordinates Ac-225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225Ac-ABD147
Description: A delta-like ligand 3 (DLL3)-targeting antibody fragment conjugated with a linker-chelator that effectively coordinates Ac-225
Study: NCT06736184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (SZC)
Description: 5g/meal\*3meals/day
Study: NCT06735430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol
Description: Ciprofol for anesthesia induction (0.5mg / kg) and anesthesia maintenance (1-2.5mg/ (kg·h))

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: Propofol for anesthesia induction (2mg / kg) and maintenance of anesthesia (4-10 mg / (kg·h))
Study: NCT06736340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rupatadine
Description: 10mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rupatadine
Description: 10mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rupatadine
Description: 10mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rupatadine
Description: 10mg tablets
Study: NCT06735755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEAM-301: Single dose of BEAM-301 administered by IV
Description: BEAM-301 is designed to correct the G6PC1 c.247C\>T allele via an A:T-to-G:C base-pair substitution, resulting in restoration of G6Pase-α catalytic activity.
Study: NCT06735781

Intervention type: DRUG
Intervention: Nivolumab
Description: As prescribed by the treating clinician
Study: NCT05406752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol Uniflash (125 mg/ 1.25 mL)
Description: Oromucosal solution (125 mg/ 1.25 mL) for buccal route
Study: NCT05930782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperaquine Phosphate
Description: PQP hard tablet 320 mg; single dose (320 mg) given orally with 240 ml of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine Phosphate
Description: PQP dispersible granules 320 mg dose equivalent dispersed in 25 ml of water; single dose (320 mg) given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine Phosphate
Description: PQP dispersible granules 320 mg dose equivalent dispersed in 25 ml of water; single dose (320 mg) given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine Phosphate
Description: PQP dispersible granules 320 mg dose equivalent dispersed in 25 ml of water; single dose (320 mg) given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine Phosphate
Description: PQP dispersible granules 320 mg dose equivalent dispersed in 25 ml of water; single dose (320 mg) given orally
Study: NCT05280951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focused-PPC Care
Description: Individual clinical assessments and counseling for each group member will last about 15 minutes. Then, there will be 1 hour of group time dedicated to education and support. Each group session will be led by two trained and registered midwives who will provide both clinical care, education, and support as needed. In addition, each group session will be supported by a project assistant. Focused-PPC will be implemented in addition to newborn care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Women in the control group will receive standard postnatal care (PNC) currently practiced in the health centers. This involves attending PNC visits at the health center within 14 days after birth, at 6 weeks, and monthly thereafter up to one year.
Study: NCT05027763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high-fiber/low fat
Description: high fiber/low fat preoperative diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fermented
Description: fermented preoperative diet
Study: NCT05471908

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: As-needed follow up
Description: At hospital discharge, participant receives a recommendation for PRN follow-up. Recommendation informs participant that scheduling a follow-up visit is not needed at discharge and suggests that participant follow symptoms after discharge to decide if a visit is ultimately needed or not.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Automatic follow-up
Description: At hospital discharge, participant receives a recommendation for automatic follow-up. Recommendation instructs participant to schedule a follow-up visit and attend the visit even if symptoms get better.
Study: NCT06491407

Intervention type: DIAGNOSTIC_TEST
Intervention: Chewing and swallowing performance assessment and related factors
Description: In the study, the dependent variables, chewing performance, will be evaluated with the Chewing and Swallowing Test of Solids, and swallowing performance will be assessed with the Repetitive Saliva Swallowing Test and Dysphagia Limit. Independent variables affecting chewing and swallowing performance have been considered within the scope of the ICF, and all possible factors determined for both geriatrics and swallowing have been listed, and the evaluation parameters and assessment tools have been decided.
Study: NCT05745675

Intervention type: DEVICE
Intervention: Pulse oximeter
Description: OLV-4202 pulse oximeter SW version: 01-15)
Study: NCT05273957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case Manager
Description: Patients are followed up by a nurse specialist in parkinsonism (case manager) who interacts with the treating neurologist and a multidisciplinary team

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care
Description: Patients are managed only by the neurologist according the institution's clinical practice
Study: NCT05529823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: warm shower
Description: A warm shower will be applied for 20 minutes to the pregnant woman whose cervical dilatation reaches 4-5 cm and 7-8 cm.
Study: NCT05111847

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baseplates with two types of adhesives are tested: 3M 1522 & Nitto ST-2410WD
Description: Baseplates with two different types of adhesives are placed behind the ears; One baseplate with one of the two types of the adhesive behind each ear

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baseplates with two types of adhesives are tested: Amparo 130002 & 3M 2480
Description: Baseplates with two different types of adhesives are placed behind the ears; One baseplate with one of the two types of the adhesive behind each ear
Study: NCT04725383

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amitriptyline
Description: Amitriptyline is a tricyclic antidepressant being studied off-label here for repetitive behaviors in autism spectrum disorders.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: amitriptyline
Description: Amitriptyline is a tricyclic antidepressant being studied off-label here for repetitive behaviors in autism spectrum disorders.
Study: NCT05146362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vermont RETAIN
Description: RETAIN projects include a combination of medical provider services, stay-at-work/return-to-work (SAW/RTW) coordination services, and other SAW/RTW services. The evaluation compares the treatment group that is eligible to receive the full set of RETAIN intervention activities and a control group that is not.
Study: NCT04906616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mlambe
Description: A combined economic and relationship-strengthening intervention at the couple level to redirect funds spent on alcohol into financial investments (e.g., education, income-generating business) and to improve couple relationships and adherence to ART.
Study: NCT06512272

Intervention type: OTHER
Group type: OTHER
Intervention: Video recorded shared using a mobile application
Description: The routine hospital discharge explanation is video recorded \[up to three minutes\].~The video is uploaded by to a mobile app for the patient and patient/ relatives can review the advice multiple times
Study: NCT03963453

Intervention type: OTHER
Intervention: Physical Exercise
Description: Physical exercise are prescribed to be performed three times per week for a year